Amgen announced compelling data from a 12,000-patient trial demonstrating that its cholesterol-lowering drug Repatha significantly reduces the risk of heart disease death, heart attacks, and strokes even in patients without prior events. These findings expand the therapeutic potential of PCSK9 inhibitors beyond high-risk groups, potentially broadening patient access. The results were highlighted by investment analysts as a positive catalyst for increasing market penetration, with Repatha sales up 22% in 2024. This breakthrough could reshape cardiovascular prevention strategies globally.